Work

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

Year: 2017

Type: article

Source: The Lancet Haematology

DOI: 10.1016/s2352-3026(17)30028-5

Authors: Sonali M Smith, Sonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, Nancy L Bartlett, Nina Wagner-Johnston, Steven I Park, Kristy L Richards, Amanda F Cashen, Anthony Jaslowski, Scott E Smith, Scott E Smith, Bruce D Cheson, Eric Hsi, John P Leonard

Institutions: University of Chicago, Duke University, Washington University in St. Louis, University of North Carolina at Chapel Hill, MedStar Georgetown University Hospital, Cleveland Clinic, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1406545193, Alliance Statistics and Data Management Center, Washington University/ Siteman Cancer Center Lead Academic Site, G2184918994, G3236675860, G3581085865, G3690325657, G4040562365, G4185274752, G6710502012, NCTN Lead Academic Participating Sites Application, Alliance for Clinical Trials in Oncology Operations Center

OpenAlex ID: W2596568008

FWCI: 10.01

Cites: 26

Cited by: 80

Related to: 10